Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Seeking Alpha
Lynn Seely - Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director Presentation Lynn Seely Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director Thank you, and thank you to TD Cowen for inviting me to present here today. I'm delighted to tell you about Lyell Immunopharma, a cell therapy company focused on bringing next-generation cell therapy to patients with cancer. We're looking to deliver the full promise of cell therapy to defeat cancer. I will be making forward-looking statements during this presentation. So please consult our securities filings and website for additional information. So at Lyell, our purpose is to give patients the gift of time. We do this by advancing next-generation CAR T-cell therapies to improve outcomes for patients with first-in-class cell therapies, innovative for hematologic malignancies and solid tumors. Our goal is really to allow patients with a one-time treatment w
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsGlobeNewswire
- Lyell Immunopharma (LYEL) is now covered by Citizens Jmp. They set a "market outperform" rating and a $34.00 price target on the stock.MarketBeat
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer GlobeNewswire
LYEL
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 3
- 3/12/26 - Form S-8
- LYEL's page on the SEC website